Pmid1992149C9 | 786611-53-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: Pmid1992149C9
• 英文别名: (E,3R,5S)-7-[5-(4-fluorophenyl)-3-propan-2-yl-1-pyrazin-2-ylpyrazol-4-yl]-3,5-dihydroxyhept-6-enoic acid
• CAS: 786611-53-8
• 化学式: C₂₃H₂₅FN₄O₄
• 分子量: 440.474
• InChiKey: DPRJPRMZJGWLHY-HNGSOEQISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  32
• 可旋转键数：
  9
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.3
• 拓扑面积：
  121
• 氢给体数：
  3
• 氢受体数：
  8

反应信息

• 作为反应物：
  描述：

  Pmid1992149C9 以47%的产率得到
  参考文献：
  名称：

  PICARD, JOSEPH A.;ROTH, BRUCE D.;SLISKOVIC, DRAGO R.

  摘要：

  DOI：
• 作为产物：
  描述：

  1-(4-氟苯基)-4-甲基戊-1,3-二酮 在 manganese(IV) oxide 、 sodium hydroxide 、 sodium tetrahydroborate 、 N-溴代丁二酰亚胺(NBS) 、 bis(triphenylphosphine)palladium(II)-chloride 、 三乙基硼 、 二异丁基氢化铝 、 三乙胺 、 magnesium bromide 、 lithium diisopropyl amide 、 三甲基乙酸 作用下， 以 甲醇 、 二氯甲烷 、 溶剂黄146 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 60.0h， 生成 Pmid1992149C9
  参考文献：
  名称：

  Inhibitors of cholesterol biosynthesis. 6. trans-6-[2-(2-N-heteroaryl-3,5-disubstituted-pyrazol-4-yl)ethyl/ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-ones

  摘要：

  A series of N-heteroaryl-substituted mevalonolactones were prepared and evaluated for their ability to inhibit the enzyme HMG-CoA reductase both in vitro and in vivo, and to lower plasma cholesterol in a hypercholesterolemic dog model. The goal of the strategy employed was to design an inhibitor which possessed the pharmacological properties of lovastatin (1), and the physicochemical properties (increased hydrophilicity) of pravastatin (2). Two compounds 20a and 20b, were more potent than lovastatin at inhibiting cholesterol biosynthesis both in vitro and in vivo. In terms of plasma cholesterol lowering, 20a was much more efficacious than lovastatin. In addition to possessing increased biological activity, these compounds are significantly less lipophilic than lovastatin, in fact, 20b has a CLOGP value comparable to pravastatin.

  DOI：

  10.1021/jm00089a022

文献信息

• PICARD, JOSEPH A.;ROTH, BRUCE D.;SLISKOVIC, DRAGO R.
  作者：PICARD, JOSEPH A.、ROTH, BRUCE D.、SLISKOVIC, DRAGO R.

  DOI：——

  日期：——
• Inhibitors of cholesterol biosynthesis. 6. trans-6-[2-(2-N-heteroaryl-3,5-disubstituted-pyrazol-4-yl)ethyl/ethenyl]tetrahydro-4-hydroxy-2H-pyran-2-ones
  作者：D. R. Sliskovic、C. J. Blankley、B. R. Krause、R. S. Newton、J. A. Picard、W. H. Roark、B. D. Roth、C. Sekerke、M. K. Shaw、R. L. Stanfield

  DOI：10.1021/jm00089a022

  日期：1992.5

  A series of N-heteroaryl-substituted mevalonolactones were prepared and evaluated for their ability to inhibit the enzyme HMG-CoA reductase both in vitro and in vivo, and to lower plasma cholesterol in a hypercholesterolemic dog model. The goal of the strategy employed was to design an inhibitor which possessed the pharmacological properties of lovastatin (1), and the physicochemical properties (increased hydrophilicity) of pravastatin (2). Two compounds 20a and 20b, were more potent than lovastatin at inhibiting cholesterol biosynthesis both in vitro and in vivo. In terms of plasma cholesterol lowering, 20a was much more efficacious than lovastatin. In addition to possessing increased biological activity, these compounds are significantly less lipophilic than lovastatin, in fact, 20b has a CLOGP value comparable to pravastatin.